4.8 Editorial Material

Global Impact of 2017 American Heart Association/American College of Cardiology Hypertension Guidelines A Perspective From Japan

期刊

CIRCULATION
卷 137, 期 6, 页码 543-545

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCULATIONAHA.117.032851

关键词

blood pressure monitoring; ambulatory; Japan

资金

  1. Teijin Pharma, Ltd
  2. Omron Healthcare Co, Ltd
  3. Fukuda Denshi
  4. Bayer Yakuhin, Ltd
  5. AD Co, Ltd
  6. Daiichi Sankyo Co, Ltd
  7. Mochida Pharmaceutical Co, Ltd
  8. EA Pharma
  9. Boehringer Ingelheim Japan Inc
  10. Tanabe Mitsubishi Pharma Corp
  11. Shionogi Co, Ltd
  12. MSD KK
  13. Sanwa Kagaku Kenkyusho Co, Ltd
  14. Bristol-Myers Squibb KK
  15. Grants-in-Aid for Scientific Research [26293192] Funding Source: KAKEN

向作者/读者索取更多资源

The 2017 American Heart Association/American College of Cardiology (AHA/ACC) guidelines for the prevention, detection, evaluation, and management of high blood pressure (BP) in adults were recently released. 1 The core concept in these guidelines is earlier and tighter BP control over 24 hours, with the aim of providing more sustained target organ protection and cardiovascular disease prevention. These guidelines lower the threshold of hypertension diagnosis and target BP levels to 130/80 mm Hg. This direction of strict BP control with a new definition and universal target goal for hypertension will be the topic of debate among the guideline developing committee members of the Japanese Society of Hypertension.(2)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据